We are pleased to announce that OptoSeeker has completed an Angel+ financing round raising tens of millions of RMB. This round was led by Inno Angel Fund with participation from Nanshan Capital, Hedinger Capital, ZVC Investment, and Shanghai Angel Cornerstone. The proceeds will be allocated across three strategic priorities:
Comprehensive enhancement of opto-microfluidics product lines to improve precision and efficiency of the OptoBot® series in cell screening applications;
Development and commercialization of Bio-MEMS technology for neuroscience and digital microfluidics applications;
Establishment of a global service network with full-cycle customer support to accelerate industrialization of domestically developed high-end instruments.
I: Proprietary Innovation
As one of few global companies mastering core optoelectronic tweezer (OET) technology, OptoSeeker is committed to delivering innovative, high-throughput, high-precision, and cost-effective cell screening tools. Our R&D team – comprising academic scientists and industry engineers – has achieved full in-house development from prototype to mass production, including hardware, software, and consumables. We advance OET and microfluidics applications across life sciences, materials science, and nanotechnology.
OptoSeeker integrates cross-disciplinary expertise in optics, mechanics, electronics, automation, analytical chemistry, and software engineering. Headquartered in Shenzhen’s Nanshan District, our facilities include:
-
R&D Center: Conducting autonomous forward-development to localize OET instrument cores, while driving iterative innovation through AI and big data integration.
-
Production Center: Executing modular-to-complete instrument assembly with full in-house manufacturing of consumables, ensuring product stability and scalable output.
II: Dual Product Lines
Cell screening is indispensable across life sciences – from antibody discovery and cell line development to genomics, transcriptomics, proteomics, drug screening, and extracellular detection. OptoSeeker’s fully localized OptoBot® series delivers comprehensive solutions for both research and industrial users. Customizable chip consumables accommodate varying throughput requirements, enabling higher efficiency at lower costs.
Left: OptoBot®500; Right: OptoBot®1000
Beyond OET instruments, OptoSeeker’s Bio-MEMS portfolio diversifies our offerings with platforms including the OptoNeuroBot® structured light projection system and DropletBot® digital microfluidics platform. Both lines have gained rapid customer adoption with accelerating order growth. We are executing a dual-track global expansion strategy (‘China + International’) to advance ‘Designed in China’ instrumentation worldwide.
Left: OptoNeuroBot® structured light projection platform; Right: DropletBot® digital microfluidics platform
III: Investor Perspectives
David Zhu, Managing Partner, Inno Angel Fund:
"Inno Angel prioritizes life science innovation. We endorse OptoSeeker’s robust R&D and commercialization capabilities. Their OET instruments provide transformative solutions for antibody discovery, cell/gene therapy (CGT), and synthetic biology, and we anticipate further industry-defining contributions."
Qing Xiao, Investment Director, Nanshan Capital:
"OptoSeeker fills critical gaps in China’s high-end life science instrumentation through proprietary OET technology and interdisciplinary R&D. Their precision tools empower antibody and gene therapy development, aligning perfectly with Shenzhen’s tech ecosystem. We support their local-to-global strategy for upgrading China’s biopharma supply chain."
Xiaozhong Huang, Investment Director, Hedinger Capital:
"Scientific instrumentation demands long-term iteration from components to systems. Supply chain constraints severely impact labs and downstream users. As one of China’s few OET technology masters, OptoSeeker addresses these bottlenecks, advancing domestic sovereignty in this strategic sector."
Lianfa Zheng, Partner, ZVC Investment:
"Rapid life science innovation – including CRISPR/Cas9, single-cell sequencing, and AI diagnostics – requires advanced instrumentation. We are highly confident in OptoSeeker’s product development and innovation capabilities."
IV: Corporate Vision
Hainan Xie, Co-founder & CEO:
"We extend gratitude to shareholders and our execution-focused team. Following strong market acceptance of OptoBot®500, we will intensify global promotion and accelerate launches of OptoBot®1000/2000. OptoSeeker remains committed to autonomous R&D, enabling true import substitution for automated cell processing workflows."
Corporate Profile
OptoSeeker
OptoSeeker pioneers high-end life science instrumentation through core innovations. Founded by professors from Beijing Institute of Technology, Southern University of Science and Technology (SUSTech), and Jinan University alongside overseas-returned PhDs, we accelerate biopharmaceutical and CGT research while resolving critical technology bottlenecks.
InnoAngel Fund
Founded in April 2013 with multi-billion RMB AUM, InnoAngel has backed 500+ startups in IT, new energy, advanced manufacturing, and biotech. It focuses on Angel/Pre-A stages, committed to being entrepreneurs’ first check.
Nanshan Capital
A state-backed VC under Shenzhen Nanshan SASAC, managing 5B+ RMB funds. Key investments include Dynanonic, Winlaser, Cambricon, and MicroPoint Biotech. Focus: IT, smart manufacturing, healthcare, and new materials.
Hedings Venture Capital
Invests in China’s strategic needs: AI, advanced manufacturing, new energy, biomedicine, and semiconductors. Primarily targets Seed-to-Series A with "patient capital" philosophy.
Lingyi Capital
Early-stage VC founded in 2022 with 1B+ RMB AUM. Backed by seasoned investors and listed company founders, it focuses on hard tech, healthcare, and AI.
Shanghai Angel Partners
Platform established under Shanghai government guidance to foster angel investment in hard tech and scientific commercialization.
